Related references
Note: Only part of the references are listed.Serum HE4 as a prognostic marker in endometrial cancer - A population based study
Donal. J. Brennan et al.
GYNECOLOGIC ONCOLOGY (2014)
Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in Relation to Ovarian Cancer Risk and Survival
Kristina A. Williams et al.
PLOS ONE (2014)
Comparison of Serum Human Epididymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and Nonmalignant Diseases
Jose M. Escudero et al.
CLINICAL CHEMISTRY (2011)
Minimal deviation mucinous adenocarcinoma ('adenoma malignum') of the uterine corpus
Kaoru Abiko et al.
PATHOLOGY INTERNATIONAL (2010)
Gynecologic oncology group trials in uterine corpus malignancies: recent progress
David Scott Miller et al.
Journal of Gynecologic Oncology (2009)
Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus
Richard G. Moore et al.
GYNECOLOGIC ONCOLOGY (2008)
The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma
FD Cirisano et al.
GYNECOLOGIC ONCOLOGY (2000)
Share Paper
